The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …"

Loss of ECRG4 expression decreases neutrophil mobilization from bone marrow reserves. حسب Katie D. Pool (20141584)

الموضوعات:

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. حسب Guihua Wang (286390)

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. حسب Yue Chen (73753)

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. حسب Chengjun Yu (12136227)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. حسب Rodrigo Ibarra-García-Padilla (19697623)

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. حسب Montserrat Llanses Martinez (17797522)

Naringenin decreases mitochondrial function. حسب Lauren A. Eanes (20995499)

Conventional agriculture increases global warming while decreasing system sustainability حسب Ahmed I. Abdo (13269798)

Noise decrease rate comparison. حسب Xianlin Ren (22783589)

Masking distance decreases pupillary responses. حسب Inmaculada Márquez (19681346)

Root-mean-square fluctuation (RMSF) analysis of wild-type and p.R163C mutant αB-crystallin dimers from molecular dynamics simulations. حسب Aref Baharvand (21713886)

الموضوعات:

Thermoneutrality decreased sepsis survival. حسب Goldia Chan (21453340)

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: